Benzinga | Sep 7, 2021 09:54AM EDT

United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients

United Therapeutics Corporation (NASDAQ:UTHR) has presented new clinical data from the BREEZE study evaluating Tyvaso DPI (treprostinil) in patients with pulmonary arterial hypertension (PAH).

* Related Content: In June FDA Accepted Tyvaso DPI Application Under Priority Review.

* United Therapeutics has developed Tyvaso DPI under a collaboration and license agreement with MannKind Corporation (NASDAQ:MNKD)

* Data were presented at the European Respiratory Society (ERS) International Congress 2021.

* Tyvaso DPI is a next-generation dry powder formulation of Tyvaso (treprostinil) Inhalation Solution, currently under FDA review.

* If approved, Tyvaso DPI is expected to provide a more convenient administration method than traditional nebulized Tyvaso therapy.

* The transition from nebulized Tyvaso to Tyvaso DPI demonstrated safety and tolerance with significant improvements in six-minute walk distance (6MWD) and other key factors.

* Three weeks after switching from Tyvaso to Tyvaso DPI, patients demonstrated improvements of 11.5 meters in 6MWD compared to baseline.

* Significant improvements were observed in overall satisfaction with the Tyvaso DPI inhaler.

* Significant improvements in PAH impacts were observed in physical impacts and cognitive/emotional impacts.

* Price Action: UTHR shares are down 1.02% at $208.66, while MNKD stock is up 1.91% at $4.81 during the market session on the last check Tuesday.